

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except share and per share data)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2020	2019	2020	2019
Grant and collaboration revenue	\$ 441	\$ 210	\$ 1,157	\$ 574
Operating expenses:				
Research and development	462	451	1,270	1,007
General and administrative	427	413	930	923
	<u>889</u>	<u>864</u>	<u>2,200</u>	<u>1,930</u>
Loss from operations	(448)	(654)	(1,043)	(1,356)
Other income (expense), net	(7)	-	(8)	-
Net loss	<u>\$ (455)</u>	<u>\$ (654)</u>	<u>\$ (1,051)</u>	<u>\$ (1,356)</u>
Loss per common share	<u>\$ (0.03)</u>	<u>\$ (1,994.35)</u>	<u>\$ (0.11)</u>	<u>\$ (4,706.95)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands)

	June 30, 2020	Dec. 31, 2019
Assets:		
Cash and cash equivalents	\$ 711	\$ 283
Other current assets	227	164
Total current assets	<u>938</u>	<u>447</u>
Property and other assets, net	20	22
Total assets	<u>\$ 958</u>	<u>\$ 469</u>
Liabilities and stockholders' equity (deficiency)		
Total liabilities	\$ 2,808	\$ 2,043
Stockholders' equity (deficiency)	(1,850)	(1,574)
Total liabilities and stockholders' equity (deficiency)	<u>\$ 958</u>	<u>\$ 469</u>
Common Shares Outstanding	13,834,075	299,835